Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-23
2008-12-30
Wilson, Michael C. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210
Reexamination Certificate
active
07470675
ABSTRACT:
The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ω and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination. Furthermore, the invention relates to compositions and methods to deliver polynucleotides encoding polypeptides to vertebrate cells in vivo, where the composition comprises an aqueous solution of sodium phosphate.
REFERENCES:
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5120832 (1992-06-01), Goeddel et al.
patent: 5229272 (1993-07-01), Paul et al.
patent: 5231176 (1993-07-01), Goeddel et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5268169 (1993-12-01), Brandely et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5578475 (1996-11-01), Jessee
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5910488 (1999-06-01), Nabel et al.
patent: 5994317 (1999-11-01), Wheeler
patent: 6022874 (2000-02-01), Wheeler
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6413942 (2002-07-01), Felgner et al.
patent: 6586409 (2003-07-01), Wheeler
patent: 6670332 (2003-12-01), Wheeler
patent: 6673776 (2004-01-01), Felgner et al.
patent: 6696424 (2004-02-01), Wheeler
patent: 6706694 (2004-03-01), Wolff et al.
patent: 6867195 (2005-03-01), Felgner et al.
patent: 6875748 (2005-04-01), Manthorpe et al.
patent: 7250404 (2007-07-01), Felgner et al.
patent: 2003/0186913 (2003-10-01), Wolff et al.
patent: 2003/0203863 (2003-10-01), Hobart et al.
patent: 2004/0023911 (2004-02-01), Felgner et al.
patent: 2004/0132683 (2004-07-01), Felgner et al.
patent: 1 169 793 (1984-06-01), None
patent: 0 170 204 (1986-02-01), None
patent: 0 465 529 (1998-04-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 94/29469 (1994-12-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 95/14381 (1995-06-01), None
patent: WO 95/14651 (1995-06-01), None
patent: WO 95/17373 (1995-06-01), None
patent: WO 96/18372 (1996-06-01), None
patent: WO 96/26179 (1996-08-01), None
patent: WO 96/40962 (1996-12-01), None
patent: WO 96/40963 (1996-12-01), None
patent: WO 96/41873 (1996-12-01), None
patent: WO 97/00085 (1997-01-01), None
patent: WO 97/00241 (1997-01-01), None
patent: WO 97/30089 (1997-08-01), None
patent: WO 98/08947 (1998-03-01), None
patent: WO 99/26663 (1999-06-01), None
patent: WO 99/64615 (1999-12-01), None
Horton, Cancer Research, Aug. 15, 1999, vol. 59, p. 4064-4068.
Acsadi, G., et al., “Direct Gene Transfer and Expression into Rat Heart in Vivo,”New Biol. 3:71-81, W.B. Saunders (1991).
Adachi, T., et al., “Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin,”Cancer Immunol. Immunother. 37:1-6, Springer-Verlag (1993).
Adolf, G.R., “Monoclonal Antibodies and Enzyme Immunoassays Specific for Human Interferon (INF) ω1: Evidence that IFN-ω1 is a Component of Human Leukocyte IFN,”Virology 175:410-417, Elsevier Science Ltd. (1990).
Adolf, G.R., et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,”Biochim. Biophys. Acta 1089:167-174, Elsevier Science Ltd. (1991).
Adolf, G.R., “Human interferon omega-a review,”Multiple Sclerosis 1:S44-S47, SAGE Publications (1995).
Almadrones, L., et al., “Arterial, Peritoneal, and Intraventricular Access Devices,”Sem. Oncol. Nursing 11:194-202, W.B. Saunders (1995).
Aihara, H. and Miyazaki, J.-I., “Gene transfer into muscle by electroporation in vivo,”Nature Biotechnol. 16:867-870, Nature America Publishing (Sep. 1998).
Aoki, K., et al., “Gene Therapy for Peritoneal Dissemination of Pancreatic Cancer by Liposome-Mediated Transfer of Herpes Simplex Virus Thymidine Kinase Gene,”Human Gene Therapy 8:1105-1113, Mary Ann Liebert, Inc. (Jun. 1997).
Baron, S., et al., “The Interferons. Mechanisms of Action and Clinical Applications,”JAMA 266:1375-1383, American Medical Association (1991).
Bast, Jr., R.C., et al., “Immunotherapy of a Murine Ovarian Carcinoma withCorynebacterium parvumand SpecificHeteroantiserum. I. Activation of Peritoneal Cells to Mediate Antibody-Dependent Cytotoxicity,”J. Immunol. 123:1945-1951, American Association of Immunologists (1979).
Beatty, J.D., et al., “Liposomes as immune adjuvants: T cell dependence,”Surgery 96:345-351, Mosby-Year Book (1984).
Belldegrun, A., et al., “Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines,”J. Natl. Cancer Inst. 85:207-216, Oxford University Press (1993).
Beller, U., et al., “Phase IB Study of Low-Dose Intraperitoneal Recombinant Interleukin-2 in Patients with Refractory Advanced Ovarian Cancer: Rationale and Preliminary Report,”Gynecol. Oncol. 34:407-412, Academic Press (1989).
Benedetti Panici, P., et al., “Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look,”Cancer Treatment Rev 16(Suppl. A):123-127, Academic Press (1989).
Berek, J.S., et al., “Immunotherapy with Biochemically Dissociated Fractions ofPropionibacterium acnesin a Murine Ovarian Cancer Model,”Cancer Res. 44:1871-1875, American Association for Cancer Research (1984).
Bramson, J., et al., “Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine: In Vitro and In Vivo Production of Biologically Active Interleukin-12,”Hum. Gene Ther. 7:333-342, Mary Ann Liebert, Inc. (Feb. 1996).
Brunda, M.J., et al., “Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors,”J. Exp. Med. 178:1223-1230, The Rockefeller University Press (1993).
Budker, V., et al., “The efficient expression of intravascularly delivered DNA in rat muscle,”Gene Ther. 5:272-276, Nature Publishing Group (1998).
Capon, D.J., et al., “Two Distinct Families of Human and Bovine Interferon-α Genes Are Coordinately Expressed and Encode Functional Polypeptides,”Mol. Cell. Biol. 5:768-779, American Society of Microbiology (1985).
Chapman, P.B., et al., “A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma,”Investig. New Drugs 6:179-188, Kluwer Academic Publishers (1988).
Chen, Y., et al., “DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-Expressing Mammary Tumors,”Canc. Res. 58:1965-1971, American Association for Cancer Research (May 1998).
Childers, J.M., et al., “Laparoscopic Surgical Staging of Ovar
Felgner Philip L.
Hartikka Jukka
Horton Holly
Manthorpe Marston
Parker Suezanne
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
Wilson Michael C.
LandOfFree
Methods for treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4029360